Holen Sie sich die Stockscreener-App
8.24
0.72%
-0.06
Handel nachbörslich:
8.01
-0.23
-2.79%
Schlusskurs vom Vortag:
$8.30
Offen:
$8.3
24-Stunden-Volumen:
420.26K
Relative Volume:
1.08
Marktkapitalisierung:
$2.59B
Einnahmen:
$391.87M
Nettoeinkommen (Verlust:
$-441.45M
KGV:
-4.4541
EPS:
-1.85
Netto-Cashflow:
$-301.21M
1W Leistung:
-0.96%
1M Leistung:
+2.62%
6M Leistung:
+0.49%
1J Leistung:
-35.88%
1-Tages-Spanne:
$7.97
$8.30
1-Wochen-Bereich:
$7.97
$8.96
52-Wochen-Spanne:
$7.35
$13.70
Alvotech Stock (ALVO) Company Profile
Vergleichen Sie ALVO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
8.24 | 2.59B | 391.87M | -441.45M | -301.21M | -1.85 |
|
ZTS
Zoetis Inc
|
141.11 | 63.55B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.71 | 44.47B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.00 | 40.17B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.03 | 22.99B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
440.00 | 20.14B | 3.08B | 1.24B | 1.07B | 25.61 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-23 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-14 | Eingeleitet | UBS | Buy |
| 2024-01-29 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-09-21 | Eingeleitet | Barclays | Equal Weight |
| 2022-09-07 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-06 | Herabstufung | Citigroup | Buy → Sell |
| 2022-07-26 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Alvotech Aktie (ALVO) Neueste Nachrichten
Volume spikes in Alvotech stock – what they meanWeekly Volume Report & Safe Capital Growth Trade Ideas - newser.com
Statistical indicators supporting Alvotech Equity Warrant’s strengthPortfolio Update Summary & Real-Time Chart Pattern Alerts - newser.com
How to read the order book for AlvotechJuly 2025 Price Swings & Capital Protection Trading Alerts - newser.com
Using Ichimoku Cloud for Alvotech technicalsCPI Data & Stock Market Timing Techniques - newser.com
Analyzing Alvotech with risk reward ratio chartsJuly 2025 Reactions & Free Daily Entry Point Trade Alerts - newser.com
Will Alvotech (Z45) stock beat revenue estimatesJuly 2025 Highlights & Growth Oriented Trade Recommendations - newser.com
Will Alvotech Equity Warrant stock benefit from green energy trendsJuly 2025 Catalysts & Safe Investment Capital Preservation Plans - newser.com
News impact scoring models applied to Alvotech Equity Warrant2025 Major Catalysts & Entry Point Confirmation Signals - newser.com
Alvotech Equity Warrant stock trend outlook and recovery path2025 Technical Patterns & Real-Time Buy Signal Notifications - newser.com
Comparing Alvotech Equity Warrant in custom built stock radarsM&A Rumor & Technical Pattern Based Signals - newser.com
What does recent volatility data suggest for AlvotechJuly 2025 Fed Impact & AI Based Buy and Sell Signals - newser.com
Alvotech's (ALVO) Sell (E+) Rating Reiterated at Weiss Ratings - MarketBeat
Here's How Alvotech is Expanding its Portfolio Beyond Immunology - MSN
Alvotech And Advanz Celebrate EU Omalizumab Filing - insights.citeline.com
My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
Alvotech’s AVT23 Biosimilar Gains EMA Acceptance - TipRanks
ALVO: EMA Begins Review of AVT23; Advanz Holds Commercial Rights - Stock Titan
Will Alvotech Equity Warrant stock recover after recent dropBuy Signal & Momentum Based Trading Ideas - newser.com
EMA accepts application for Alvotech's AVT23 - Biostock
Advanz Pharma and Alvotech Announce EMA Acceptance of Marketing Application for Biosimilar AVT23 to Xolair® - Quiver Quantitative
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency - Yahoo
Real time breakdown of Alvotech Equity Warrant stock performanceQuarterly Profit Report & Daily Profit Focused Screening - newser.com
EMA Recommendations for AVT03 and Gobivaz Could Be a Game Changer for Alvotech (ALVO) - simplywall.st
Will Alvotech benefit from macro trendsTrade Exit Report & Verified Short-Term Trading Plans - newser.com
Visual analytics tools that track Alvotech performanceJuly 2025 News Drivers & Accurate Entry and Exit Point Alerts - newser.com
Can Alvotech Equity Warrant recover in the next quarterPortfolio Risk Report & Reliable Entry Point Alerts - newser.com
A Fresh Look at Alvotech (NasdaqGM:ALVO) Valuation as Investors Weigh Biotech Prospects - simplywall.st
A Fresh Look at Alvotech (NasdaqGM:ALVO) Valuation After Recent Stock Uptick - Yahoo Finance
Alvotech (NasdaqGM:ALVO): Is the Market Overlooking Its True Value? - simplywall.st
Is Alvotech (Z45) stock a safe buy pre earningsEarnings Recap Report & Accurate Technical Buy Alerts - newser.com
How supply chain issues affect Alvotech Equity Warrant stockEarnings Summary Report & Expert Curated Trade Setup Alerts - newser.com
Alvotech Equity Warrant stock trendline breakdownJuly 2025 Action & Verified Entry Point Detection - newser.com
Why ETFs are accumulating Alvotech (Z45) stockQuarterly Portfolio Summary & Target Return Focused Picks - newser.com
How Alvotech Equity Warrant stock performs in high volatility markets2025 Growth vs Value & Long-Term Growth Plans - newser.com
Is Alvotech Equity Warrant stock vulnerable to regulatory risksJuly 2025 Opening Moves & AI Based Buy/Sell Signal Reports - newser.com
What candlestick patterns are forming on Alvotech Equity WarrantQuarterly Market Review & Real-Time Sentiment Analysis - newser.com
Is Alvotech Equity Warrant stock supported by innovation pipelineJuly 2025 PostEarnings & Safe Entry Zone Tips - newser.com
Volume spikes in Alvotech Equity Warrant stock – what they meanRecession Risk & Safe Entry Point Identification - newser.com
Will Alvotech stock outperform tech sector in 2025July 2025 Earnings & Smart Investment Allocation Insights - newser.com
Finanzdaten der Alvotech-Aktie (ALVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.54%
1.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):